Surge Biswas
@SurgeBiswas
CEO Nabla Bio
Test-time scaling has arrived for biological design. Excited to share new work from Nabla Bio. By scaling test-time compute, we've achieved remarkable leaps in de novo antibody design against difficult drug targets.
For a platform therapeutics company as technologically rich and fast-moving as Manifold Bio, a website is always just a snapshot in time. But I’m especially excited about this one. Our goal was to capture the scale of the tissue-targeted medicines opportunity and the uniquely…
We're live! Manifold Bio's new website is here: manifold.bio Inspired? We're growing—join us. Special thanks to @bunsenstudio for articulating our vision and Javelin Tea Creative (javelinteacreative.com) for capturing the spirit of our team. #Hiring
We’re launching AAV Apex Suite today — a new product line to support gene therapy drug developers and CDMOs. AAV gene therapies have incredible potential to cure disease, but cost and scale limitations have held them back. At @64xbio, we’re on a mission to solve these challenges…
Today we’re announcing AAV Apex Suite, a powerful suite of tools for end-to-end AAV production. The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in gene therapy continue to be held back by manufacturing constraints.…
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
AI hype or reality - can we design antibodies from scratch? In my latest article for @GENbio, I unpack how arguments over terminology have clouded the industry’s shared mission of bringing better therapeutics to the clinic faster. tinyurl.com/4uamc8c5
Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox Debates over terminology clouded the mission of bringing better therapeutics to the clinic faster @nablabio @HHMINEWS @BakerLaboratory @abscibio @generate_biomed @Caltech hubs.ly/Q03nqpw_0
Today, we’re announcing the first major discovery made by our AI Scientist with the lab in the loop: a promising new treatment for dry AMD, a major cause of blindness. Our agents generated the hypotheses, designed the experiments, analyzed the data, iterated, even made figures…
ICYMI we @Dyno_Tx unveiled 3 new capsids (delivering payloads to the Eye, CNS, and Neuromuscular) presented as oral spotlights in #ASGCT2025 this week! We also announced the first edition of the #GATC conference and our new frontiers program (if you are a startup in this space,…
Nice piece from @xiaofei_lin @GENbio on our recent advance in de novo antibody design for GPCRs
Test-Time Scaling Improves Speed and Success of AI-Based Antibody Design @nablabio's AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few months @SurgeBiswas @geochurch @harvardmed #ArtificialIntelligence hubs.li/Q03mc8nr0
Great write-up by @RobertFService at @ScienceMagazine on this work. Quotes from Wei Wang, David Baker, and Andrew Bradbury check it out: science.org/content/articl…
Test-time scaling has arrived for biological design. Excited to share new work from Nabla Bio. By scaling test-time compute, we've achieved remarkable leaps in de novo antibody design against difficult drug targets.
Check out Alli's talk on Monday 9AM at PEGS Boston. She'll be sharing a lot of new data from us
Alli will be giving a talk about some of our latest results on antibody design for GPCRs, and the protein production and characterization challenges that go along with that at PEGS Boston 9AM Monday.
Why test #celltherapies one-by-one when you can use multiplexed #SynBio, #proteinengineering & #ML to design, measure & track them at scale? The Goodman Lab @PennMedicine opens July 2025. We’re hiring Specialists & Postdocs! Apply @ bit.ly/42BnJNJ RTs appreciated!🙏
We're unaffected at @TerraformIndies by grant freezes because despite spending years asking DoE to help out our process of increasing the supply of cheap carbon free hydrocarbons, we were awarded 0/20 grants. The officials were friendly and helpful but the emergent behavior of…
You go through this incredibly arduous process and then the senior directors award discretionary funds to their buddy from grad school in 1978 who also happens to have co-authored 100 fraudulent papers.